Company

Richard Cote, M.D., FRSCPath, Chairman
Founder of Impath Oncology, chair of the Department of Pathology at the University of Miami Miller School of Medicine and the University of Miami Health System, and Chief of Pathology for Jackson Memorial Hospital, Miami, FL

Anthony Tolcher, M.D., FRCP
Director of Clinical Research, South Texas Accelerated Research Therapeutics in San Antonio

Daniel Von Hoff, M.D., FACP
Head of Translational Research at the Translational Genomics Research Institute in Phoenix and a founder of Ilex Oncology. Dr. Von Hoff is a past President of the American Association for Cancer Research is currently Editor-in-Chief of Molecular Cancer Therapeutics and was formerly on President Bush’s National Cancer Advisory Board

Roy Herbst, M.D., PhD
Professor of Medicine at MD Anderson Cancer Center in Houston. Dr. Herbst was a key investigator in the clinical development of the EGFR inhibitor, Iressa®

Charles Schiffer, M.D.
Professor of Medicine at Wayne State University. Dr. Schiffer was extensively involved in the clinical development of Gleevec® and is a former Chairman of the Oncology Drug Advisory Committee to the FDA

Philip Banks, M.A.
A biostatistician with 23 years of pharmaceutical and biotechnology industry experience who has participated in the development of seven cancer-related NDAs

Arul Chinnaiyan, M.D., Ph.D.
Director of Pathology and the Microarray Laboratory at the University of Michigan